← All trials
NCT04342221
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Feb 28, 2022
- First posted
- Apr 10, 2020
- Last posted
- Apr 10, 2020
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TuebingenLead sponsor
- University of TuebingenCollaborator
- University of HamburgCollaborator
- University of TuebingenOverall official - principal investigator
- Bernhard Nocht Institute for Tropical MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.